| |
Back to Chest Drug index
Name: Triamcinolone
|
|
|
Xolair reduced the rate of hospital emergency visits by 44% in
patients with inadequately controlled asthma.
|
|
|
|
|
| |
 related discussion |
|
|
|
|
|
|
|
|
|
|
|
Pregnancy Category C
Drug classes
- Corticosteroid (intermediate acting)
- Glucocorticoid
- Hormonal agent
Therapeutic actions
Enters target cells and binds to cytoplasmic receptors, thereby
initiating
many complex reactions that are responsible for its anti-inflammatory
and
immunosuppressive effects.
Indications
- Hypercalcemia associated with cancer (systemic)
- Short-term management of various inflammatory and allergic disorders,
such as rheumatoid arthritis, collagen diseases (eg, SLE),
dermatologic
diseases (eg, pemphigus), status asthmaticus, and autoimmune disorders
- Hematologic disorders: thrombocytopenia purpura, erythroblastopenia
- Ulcerative colitis, acute exacerbations of mutiple sclerosis, and
palliation in some leukemias and lymphomas
- Trichinosis with neurologic or myocardial involvement
- Pulmonary emphysema with bronchial spasm or edema; diffuse
interstitial
pulmonary fibrosis; with diuretics in CHF with refractory edema and in
cirrhosis with refractory ascites
Postoperative dental inflammatory reactions
- Arthritis, psoriatic plaques, and so forth (intra-articular,
soft-tissue
administration)
- Control of bronchial asthma requiring corticosteroids in conjunction
with
other therapy (respiratory inhalant)
- To relieve inflammatory and pruritic manifestations of dermatoses that
are steroid responsive (dermatologic preparations)
Contraindications/cautions
Contraindicated in the presence of infections, especially
tuberculosis,
fungal infectons, amebiasis, vaccinia and varicella, and
antibiotic-resistant infections; lactation; allergy to tartrazine in
8-mg
oral tablets marketed under the brand name Kenacort.
Use caution in the presence of pregnancy (teratogenic in preclinical
studies); kidney or liver disease, hypothyroidism, ulcerative colitis
with impending perforation, diverticulitis, active or latent peptic
ulcer, inflammatory bowel disease, CHF, hypertension, thromboembolic
disorders, osteoporosis, convulsive disorders, diabetes mellitus.
|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
Adverse effects Effects depend on dose, route, and duration of therapy.
- CNS: Vertigo, headache, paresthesias, insomnia, convulsions,
psychosis,
cataracts, increased intraocular pressure, glaucoma (long-term
therapy)
- GI: Peptic or esophageal ulcer, pancreatitis, abdominal distention,
nausea, vomiting, increased appetite, weight gain (long-term therapy)
- CV: Hypotension, shock, hypertension and CHF secondary to fluid
retention, thromboembolism, thrombophlebitis, fat embolism, cardiac
arrhythmias
- MS: Muscle weakness, steroid myopathy, loss of muscle mass,
osteoporosis, spontaneous fractures (long-term therapy)
- Hypersensitivity: Hypersensitivity or anaphylactoid reactions
- Endocrine: Amenorrhea, irregular menses, growth retardation, decreased
carbohydrate tolerance, diabetes mellitus, cushingoid state (long-term
effect), increased blood sugar, increased serum cholesterol, decreased
T3 and T4 levels, hypothalamic-pituitary-adrenal (HPA)
suppression with systemic therapy longer than 5 d
- Electrolyte imbalance: Na+ and fluid retention, hypokalemia,
hypocalcemia
- Other: Immunosuppression, aggravation, or masking of infections;
impaired wound healing; thin, fragile skin; petechiae, ecchymoses,
purpura, striae; subcutaneous fat atrophy
Intra-articular
- Local: Osteonecrosis, tendon, rupture, infection
Intralesional (face and head)
Respiratory Inhalants
- Local: Oral, laryngeal, and pharyngeal irritation; fungal infections
Topical Dermatologic Ointments, Creams, Sprays
- Local: Local burning, irritation, acneiform lesions, striae, skin
atrophy
- Systemic absorption of dermatologic preparations can lead to HPA
suppression (see above), growth retardation in children, and other
systemic adverse effects. Children may be at special risk of systemic
absorption because of their larger skin surface to body weight ratio.
|
|
send
to a friend
printer
friendly version
